‘Doing more with less’: In-house counsel on budgets and strategy

Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Biotech

GSK and Moderna settle cross-border patent dispute over vaccine tech

11 November 2026 The parties granted each other the right to use their respective patented inventions in the field of infectious disease but are not obligated to make any payments in connection with the licences.

Biotech

Regeneron and Amgen call a truce on two Eylea biosimilar patents

28 October 2026 Both companies have agreed to dismiss claims and counterclaims involving Amgen’s 2 mg aflibercept biosimilar, while their wider feud continues.

Biotech

10x and Parse set to end sequencing feud after appeals court defeat

23 October 2026 Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.

More features

GSK lands 36-country injunction in Pfizer-BioNTech vaccine litigation

‘No medicine is off limits’: US Chamber of Commerce says stricter import rules may deter fakes

GSK and Moderna settle cross-border patent dispute over vaccine tech

Eli Lilly follows Novo in UK High Court bid to block ‘black-market websites’

Irish law firms announce merger

How in-house teams can get more value from external counsel

Settled expectations, the six-year rule, and developments in USPTO policy

Regulatory and patent teams must align, say Amgen, Genentech, ORIC

‘Doing more with less’: In-house counsel on budgets and strategy

More on this story

Editor's picks

Editor's picks

More features